Lawrence A. Leiter

7 ta ish

University of Toronto

1. Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes

   Steven P. Marso, Stephen C. Bain, Agostino Consoli +12

   BoshqaOAOchiq kirish20164 iqtibos

   ABIABI:AkademIndex/2026.other.057709

2. Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes

   Stephen D. Wiviott, Itamar Raz, Marc P. Bonaca +17

   Maqola20183 iqtibos

   ABIABI:AkademIndex/2026.other.282509

3. Statin-associated muscle symptoms: impact on statin therapy—European Atherosclerosis Society Consensus Panel Statement on Assessment, Aetiology and Management

   Erik S.G. Stroes, Paul D. Thompson, Alberto Corsini +37

   Sharh maqola20153 iqtibos

   ABIABI:AkademIndex/2026.other.568881

4. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial

   Hertzel C. Gerstein, Helen M. Colhoun, Gilles R. Dagenais +97

   MaqolaOAOchiq kirish20192 iqtibos

   ABIABI:AkademIndex/2026.other.057761

5. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol

   Kausik K. Ray, R. Scott Wright, David Kallend +8

   MaqolaOAOchiq kirish20202 iqtibos

   ABIABI:AkademIndex/2026.other.057780

6. Effect of Valsartan on the Incidence of Diabetes and Cardiovascular Events

   John J McMurray, John J.V. McMurray, Steven M Haffner +51

   Maqola20102 iqtibos

   ABIABI:AkademIndex/2026.other.295648

7. Blood-Pressure and Cholesterol Lowering in Persons without Cardiovascular Disease

   Salim Yusuf, Eva Lonn, Prem Pais +29

   Maqola20162 iqtibos

   ABIABI:AkademIndex/2026.other.295802